Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2027. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics today
- Apple downgraded, Rivian initiated: Wall Street’s top analyst calls
- Cantor upgrades Beam Therapeutics to Overweight into BEAM-302 readout
- Beam Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Beam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101